SCHEMBL19259409

SCHEMBL19259409

O=c1cc(Cl)cc(-c2ccccc2Cl)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 5/20 0.56
ALDH1A1 P00352 2/20 0.49
POLB P06746 2/20 0.49
MAPT P10636 2/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TNKS2 Q9H2K2 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19259508 0.84 PIK3C3 (0.52) PIK3C3ALDH1A1POLBMAPTALOX15
SCHEMBL26503024 0.84 PIK3C3 (0.52) PIK3C3ALDH1A1POLBMAPTALOX15
SCHEMBL3757426 0.83 PIK3C3 (0.51) PIK3C3ALDH1A1POLBMAPTALOX15
SCHEMBL8987394 0.82 PIK3C3 (0.64) PIK3C3ALDH1A1POLBMAPTALOX15
SCHEMBL30602735 0.78 NOTUM (0.53) PIK3C3ALDH1A1POLBMAPTALOX15
SCHEMBL20765326 0.78 PIK3C3 (0.50) PIK3C3ALDH1A1MEN1KMT2AKDM4E
SCHEMBL8987087 0.75 PIK3C3 (0.53) PIK3C3ALDH1A1POLBMAPTALOX15
SCHEMBL19259482 0.73 PIK3C3 (1.00) PIK3C3
SCHEMBL30514771 0.73 KDM4E (0.43) PIK3C3ALDH1A1MAPTMEN1KMT2A
SCHEMBL20764787 0.72 PIK3C3 (1.00) PIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050439-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES Spring Bioscience AB (SE) 2024-02-15 US disclosed
CN-116903526-A Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-10-20 CN disclosed
CN-116891431-A Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-10-17 CN disclosed
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-10-12 US disclosed
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-10-12 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
CN-116589461-A Azaindolylpyridone compounds and diazaindolylpyridone compounds 思普瑞特生物科学公司 2023-08-15 CN disclosed
CN-116589462-A Azaindolylpyridone compounds and diazaindolylpyridone compounds 思普瑞特生物科学公司 2023-08-15 CN disclosed
CN-111247144-A Azaindolylpyridinone compounds and diazaindolylpyridinone compounds 思普瑞特生物科学公司 2020-06-05 CN disclosed
CN-111094244-A Pyridylpyridone compounds 思普瑞特生物科学公司 2020-05-01 CN disclosed
CN-111094271-A Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds 思普瑞特生物科学公司 2020-05-01 CN disclosed
WO-2019038387-A1 PYRIDYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038387-A1 PYRIDYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038384-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038389-A1 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
EP-3416945-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES Sprint Bioscience AB (SE) 2018-12-26 EP disclosed
WO-2017140841-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES SPRINT BIOSCIENCE AB (SE) 2017-08-24 WO disclosed
WO-2017140841-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES SPRINT BIOSCIENCE AB (SE) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS AZI2, IAPP, ZFX PIK3C3 1407/4885ALDH1A1 1426/4885POLB 2381/4885
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds PDXK, PLPBP, PNPO PIK3C3 3787/4885ALDH1A1 1779/4885POLB 1562/4885
US-20240050439-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES PYCR1, GPR119, CDK6 PIK3C3 4489/4885ALDH1A1 1556/4885POLB 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.